These Analysts Boost Their Forecasts On GoodRx Holdings After Q2 Results
Portfolio Pulse from Lisa Levin
GoodRx Holdings Inc (NASDAQ:GDRX) reported better-than-expected Q2 results with sales of $189.7 million, beating the consensus of $186.82 million. The company revised its FY23 sales guidance to $750-$760 million. Following the earnings announcement, several analysts including Wells Fargo, RBC Capital, Credit Suisse, Goldman Sachs, and Evercore ISI Group raised their price targets on GoodRx. The company's shares gained 7.2% to trade at $8.52 on Thursday.
August 10, 2023 | 3:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GoodRx reported better-than-expected Q2 results and revised its FY23 sales guidance, leading to a rise in its stock price and an increase in price targets by several analysts.
GoodRx's better-than-expected Q2 results and revised FY23 sales guidance are positive news for the company. This has led to an increase in its stock price and higher price targets by several analysts, indicating a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100